A notable example is MRT5005, an mRNA therapy designed for cystic fibrosis (CF), which has entered clinical trials as a protein replacement therapy targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein [311]. The gene discussed is CFTR; the disease is cystic fibrosis.